Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.

Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 3.6% ...

Regeneron’s second quarter was marked by robust growth in key products, which the company attributed to the strong commercial ...

Truist on Monday lowered its price target on Regeneron (REGN) to $812 from $940, citing concerns with the company’s Eylea ...

Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

R egeneron has received an US Food and Drug Administration (FDA) rejection for a new blood cancer therapy and expects ...

Pavblu, an Eylea HD biosimilar, shows stable vision outcomes and minimal side effects in real-world use, promising a reliable ...

When Regeneron snagged an FDA nod for eye drug Eylea in diabetic retinopathy in 2019, the agency opted against approving a 16-week dosing schedule despite positive data from a pivotal trial.

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click here to read why REGN is a Buy.

Marketing Regeneron's Eylea still sitting pretty even after new data from would-be rivals Roche, Novartis: analyst By Carly Helfand Feb 12, 2018 10:27am macular edema VEGF Eylea Lucentis ...

Given the generally solid safety profile of Eylea and this higher-dose version, we expect Regeneron and partner Bayer to gain approval in late 2023/early 2024 for this new formulation.

Based on its bullish expectation, Regeneron raised its forecast for 2013 Eylea sales. Regeneron now expects 2013 sales of Eylea in the range of $1.35-$1.375 billion (old guidance: $1.3-$1.35 billion).